Diamonds and Dogs

10/20/17

Paypal (PYPL) finding new friends. The digital payments company is up 4% to new highs following better than expected earnings. The company easily beat earnings expectations and raised sales guidance for the fourth quarter. Plenty of upgrades for Paypal this morning, but the price targets are not much higher than the current price as valuation is getting more expensive.

Celgene (CELG) taking a hit. The biotech giant is down 13% to a four month low as the company will discontinue a trial for one of their drugs to treat Crohn's disease. The drug could've been a blockbuster generating nearly $2 billion in sales. But luckily for Celgene they have one of the best drug pipelines in the industry.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.